Shawver Laura 4
4 · ARS Pharmaceuticals, Inc. · Filed Feb 4, 2025
Insider Transaction Report
Form 4
Shawver Laura
Director
Transactions
- Sale
Common Stock
2025-02-03$12.31/sh−50,000$615,565→ 210,346 total - Exercise/Conversion
Common Stock
2025-02-03$3.15/sh+9,064$28,552→ 219,410 total - Exercise/Conversion
Common Stock
2025-02-03$4.85/sh+40,936$198,540→ 260,346 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-02-03−9,064→ 0 totalExercise: $3.15Exp: 2032-05-01→ Common Stock (9,064 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-02-03−40,936→ 124,064 totalExercise: $4.85Exp: 2032-01-31→ Common Stock (40,936 underlying)
Footnotes (3)
- [F1]The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
- [F2]The weighted average sale price for the transaction reported was $12.3113 and the range of prices were between $11.9732 and $12.76. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]Immediately exercisable.